Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6515-6518

  Harrison, Bryce A ^a   Whitlock, N Andrew ^a   Voronkov, Michael V ^a   Almstead, Zheng Y ^a   Gu, Kun Jian ^a   Mabon, Ross ^a   Gardyan, Michael ^a   Hamman, Brian D ^a   Allen, Jason ^a   Gopinathan, Suma ^a   McKnight, Beth ^a   Crist, Mike ^a   Zhang, Yulian ^a   Liu, Ying ^a   Courtney, Lawrence F ^a   Key, Billie ^a   Zhou, Julia ^a   Patel, Nita ^a   Yates, Phil W ^b   Liu, Qingyun ^a   Wilson, Alan G E ^a   Kimball, S David ^a   Crosson, Craig E ^b   Rice, Dennis S ^a   Rawlins, David B ^a   more..

^a LEXICON PHARMACEUTICALS INC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIM KINASE 2 INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PYRROLOPYRIMIDINE DERIVATIVE; STEROID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYMATIC ASSAY; GLAUCOMA; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SWINE;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; GLAUCOMA; GUANIDINES; INTRAOCULAR PRESSURE; LIM KINASES; MICE; NITRILES; OCULAR HYPERTENSION; PIPERAZINES; PYRIMIDINES; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; UREA;

EID: 71049125741     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901226j     Document Type: Article

References (21)

1. Weinreb, R. N.; Toris, C. B.; Gabelt, B. T.; Lindsey, J. D.; Kaufman, P. L. Effects of prostaglandins on the aqueous humor outflow pathways. Surv. Ophthalmol. 2002, 47 (Suppl. 1), S53-S64.
2. Toris, C. B.; Koepsell, S. A.; Yablonski, M. E.; Camras, C. B. Aqueous humor dynamics in ocular hypertensive patients. J. Glaucoma 2002, 11, 253-258. (Pubitemid 34620103)
3. Friedman, D. S.; Wolfs, R. C.; O'Colmain, B. J.; Klein, B. E.; Taylor, H. R.; West, S.; Leske, M. C.; Mitchell, P.; Congdon, N.; Kempen, J. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004, 122, 532-538.
4. Coakes, R. L.; Brubaker, R. F. The mechanism of timolol in lowering intraocular pressure in the normal eye. Arch. Ophthalmol. 1978, 96, 2045-2048.
5. Toris, C. B.; Gleason, M. L.; Camras, C. B.; Yablonski, M. E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 1995, 113, 1514-1517.
6. Lippa, E. A.; Carlson, L. E.; Ehinger, B.; et al. Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 1992, 110, 495-499.
7. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp. Eye Res. 1989, 49, 389-402.
8. Schwartz, K.; Budenz, D. Current management of glaucoma. Curr. Opin. Ophthalmol. 2004, 15, 119-126.
9. Reyes, E.; Izquierdo, N. J.; Blasini, M. Adverse drugs reactions associated with glaucoma medications. Bol. - Asoc. Med. P. R. 1997, 89, 51-55.
10. Lewis, T. (Principal Author). Optometric Clinical Practice Guideline, Care of Patient with Open Angle Glaucoma: Reference Guide for Clinicians. Updated Aug 17, 2002. http://www.aoa.org/documents/CPG-9.pdf (accessed Sep 28, 2009).
11. Tanihara, H.; Inatani, M.; Honjo, M.; Tokushige, H.; Azuma, J.; Araie, M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch. Ophthalmol. 2008, 126, 309-315.
12. Arber, S.; Barbayannis, F. A.; Hanser, H.; Schneider, C.; Stanyon, C. A.; Bernard, O.; Caroni, P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature 1998, 393, 805-809. (Pubitemid 28299494)
13. Yang, N.; Higuchi, O.; Ohashi, K.; Nagata, K.; Wada, A.; Kangawa, K.; Nishida, E.; Mizuno, K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature 1998, 393, 809-812. (Pubitemid 28299495)
14. Lindsey, J. D.; Weinreb, R. N. Elevated intraocular pressure and transgenic applications in themouse. J. Glaucoma 2005, 14, 318-320. (Pubitemid 41023021)
15. John, S. W.; Anderson, M. G.; Smith, R. S. Mouse genetics: a tool to help unlock the mechanisms of glaucoma. J. Glaucoma 1999, 8, 400-412.
16. Whitlock, N. A.; Harrison, B.; Mixon, T.; Yu, X.-Q.; Wilson, A.; Gerhardt, B.; Eberhart, D. E.; Abuin, A.; Rice, D. S. Decreased intraocular pressure in mice following either pharmacological or genetic inhibition of ROCK. J. Ocul. Pharmacol. Ther. 2009, 25, 187-194.
17. Whitlock, A; Rice, D. S.; et al. et al. Manuscript in preparation.
18. We are aware of only one other report of LIM kinase inhibitors in the literature: Ross-Macdonald, P.; de Silva, H.; Guo, Q.; Xiao, H.; Hung, C.-Y.; Penhallow, B.; Markwalder, J.; He, L.; Attar, R. M.; Lin, T.; Seitz, S.; Tilford, C.; Wardwell-Swanson, J.; Jackson, D. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol. Cancer Ther. 2008, 7, 3490-3498.
19. Whitlock, A.; McKnight, B.; Rice, D. S. Increased Intraocular Pressure in Mice Treated with Dexamethasone. Abstracts of Papers, 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale, FL; Association for Research in Vision and Ophthalmology: Rockville, MD, 2008; Abstract 2100/A211.
20. West, R. A. 4-Hydroxypyrrolo[2,3-d]pyrimidine: Mannich reaction. J. Org. Chem. 1961, 26, 4959-4961.
21. The average IOP for normotensive mice in our experiments was 13.9 ± 0.9 mmHg. The average IOP for the dexamethasone induced ocular hypertensive mice was 17.7 ± 1.1 mmHg, representing a 3.8 mmHg increase from baseline.